|
|
Blood, 15 April 2004, Vol. 103, No. 8, pp. 3138-3147.
Prepublished online as a Blood First Edition Paper on December 24, 2003; DOI 10.1182/blood-2003-05-1543.
 Previous Article | Table of Contents | Next Article 
NEOPLASIA
Rapamycin sensitizes multiple myeloma cells to apoptosis induced by dexamethasone
Thomas Strömberg,
Anna Dimberg,
Anna Hammarberg,
Kristina Carlson,
Anders Österborg,
Kenneth Nilsson, and
Helena Jernberg-Wiklund
From the Department of Genetics and Pathology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden; the Department of Medical Sciences, University Hospital, Uppsala, Sweden; and the Departments of Hematology and Oncology, Karolinska Hospital, Stockholm, Sweden.
Circumvention of chemoresistance in the B-cell neoplasm multiple myeloma (MM) might be achieved by targeting certain intracellular signaling pathways crucial for survival of the malignant clone. The use of the macrolide rapamycin, selectively inhibiting the phosphoprotein mammalian target of rapamycin (mTOR) downstream of, for example, insulin-like growth factor-I receptor (IGF-IR), possibly represents such a molecular mode of therapy. By using a panel of MM cell lines we showed that rapamycin induced G0/G1 arrest, an effect being associated with an increase of the cyclin-dependent kinase inhibitor p27 and a decrease of cyclins D2 and D3. Interestingly, in primary, mainly noncycling MM cells, rapamycin, at clinically achievable concentrations, induced apoptosis. More important, rapamycin sensitized both MM cell lines and primary MM cells to dexamethasone-induced apoptosis. This effect was associated with a decreased expression of cyclin D2 and survivin. The phosphorylation of the serine/threonine kinase p70S6K at Thr389 and Thr421/Ser424 was down-regulated by rapamycin and/or dexamethasone. Strikingly, the combinatorial treatment with rapamycin and dexamethasone suppressed the antiapoptotic effects of exogenously added IGF-I and interleukin 6 (IL-6) as well as their stimulation of p70S6K phosphorylation. The induction of apoptosis by rapamycin and dexamethasone despite the presence of survival factors was also demonstrated in primary MM cells, thus suggesting this drug combination to be active also in vivo. (Blood. 2004;103:3138-3147)
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
A. Gorshtein, H. Rubinfeld, E. Kendler, M. Theodoropoulou, V. Cerovac, G. K Stalla, Z. R Cohen, M. Hadani, and I. Shimon
Mammalian target of rapamycin inhibitors rapamycin and RAD001 (everolimus) induce anti-proliferative effects in GH-secreting pituitary tumor cells in vitro
Endocr. Relat. Cancer,
September 1, 2009;
16(3):
1017 - 1027.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Frost, Y. Shi, B. Hoang, J. Gera, and A. Lichtenstein
Regulation of D-cyclin translation inhibition in myeloma cells treated with mammalian target of rapamycin inhibitors: rationale for combined treatment with extracellular signal-regulated kinase inhibitors and rapamycin
Mol. Cancer Ther.,
January 1, 2009;
8(1):
83 - 93.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. E. Mills, K. R. Taylor, K. Podshivalova, D. B. McKay, and J. M. Jameson
Defects in Skin {gamma}{delta} T Cell Function Contribute to Delayed Wound Repair in Rapamycin-Treated Mice
J. Immunol.,
September 15, 2008;
181(6):
3974 - 3983.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Q. Lacy, M. Alsina, R. Fonseca, M. L. Paccagnella, C. L. Melvin, D. Yin, A. Sharma, M. Enriquez Sarano, M. Pollak, S. Jagannath, et al.
Phase I, Pharmacokinetic and Pharmacodynamic Study of the Anti-Insulinlike Growth Factor Type 1 Receptor Monoclonal Antibody CP-751,871 in Patients With Multiple Myeloma
J. Clin. Oncol.,
July 1, 2008;
26(19):
3196 - 3203.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Q. Jin, L. Feng, C. Behrens, B. N. Bekele, I. I. Wistuba, W.-K. Hong, and H.-Y. Lee
Implication of AMP-Activated Protein Kinase and Akt-Regulated Survivin in Lung Cancer Chemopreventive Activities of Deguelin
Cancer Res.,
December 15, 2007;
67(24):
11630 - 11639.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. J. Bahlis, A. M. King, D. Kolonias, L. M. Carlson, H. Y. Liu, M. A. Hussein, H. R. Terebelo, G. E. Byrne Jr, B. L. Levine, L. H. Boise, et al.
CD28-mediated regulation of multiple myeloma cell proliferation and survival
Blood,
June 1, 2007;
109(11):
5002 - 5010.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. S. Bachmann, R. Gorman, R. A. Papa, J. E. Bardell, J. Ford, U. R. Kees, G. M. Marshall, and R. B. Lock
Divergent Mechanisms of Glucocorticoid Resistance in Experimental Models of Pediatric Acute Lymphoblastic Leukemia
Cancer Res.,
May 1, 2007;
67(9):
4482 - 4490.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Zheng, S. L. Collins, M. A. Lutz, A. N. Allen, T. P. Kole, P. E. Zarek, and J. D. Powell
A Role for Mammalian Target of Rapamycin in Regulating T Cell Activation versus Anergy
J. Immunol.,
February 15, 2007;
178(4):
2163 - 2170.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. Landgren, Y. Zhang, S. H. Zahm, P. Inskip, T. Zheng, and D. Baris
Risk of Multiple Myeloma following Medication Use and Medical Conditions: A Case-Control Study in Connecticut Women
Cancer Epidemiol. Biomarkers Prev.,
December 1, 2006;
15(12):
2342 - 2347.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Peponi, E. Drakos, G. Reyes, V. Leventaki, G. Z. Rassidakis, and L. J. Medeiros
Activation of Mammalian Target of Rapamycin Signaling Promotes Cell Cycle Progression and Protects Cells from Apoptosis in Mantle Cell Lymphoma
Am. J. Pathol.,
December 1, 2006;
169(6):
2171 - 2180.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. S. Zand, T. Vo, T. Pellegrin, R. Felgar, J. L. Liesveld, J. J. Ifthikharuddin, C. N. Abboud, I. Sanz, and J. Huggins
Apoptosis and complement-mediated lysis of myeloma cells by polyclonal rabbit antithymocyte globulin
Blood,
April 1, 2006;
107(7):
2895 - 2903.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Yan, P. Frost, Y. Shi, B. Hoang, S. Sharma, M. Fisher, J. Gera, and A. Lichtenstein
Mechanism by Which Mammalian Target of Rapamycin Inhibitors Sensitize Multiple Myeloma Cells to Dexamethasone-Induced Apoptosis
Cancer Res.,
February 15, 2006;
66(4):
2305 - 2313.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Stromberg, S. Ekman, L. Girnita, L. Y. Dimberg, O. Larsson, M. Axelson, J. Lennartsson, U. Hellman, K. Carlson, A. Osterborg, et al.
IGF-1 receptor tyrosine kinase inhibition by the cyclolignan PPP induces G2/M-phase accumulation and apoptosis in multiple myeloma cells
Blood,
January 15, 2006;
107(2):
669 - 678.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Shi, H. Yan, P. Frost, J. Gera, and A. Lichtenstein
Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade
Mol. Cancer Ther.,
October 1, 2005;
4(10):
1533 - 1540.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Y. Dimberg, A. I. Dimberg, K. Ivarsson, T. Stromberg, A. Osterborg, K. Nilsson, F. Oberg, and H. J. Wiklund
Ectopic and IFN-induced expression of Fas overcomes resistance to Fas-mediated apoptosis in multiple myeloma cells
Blood,
August 15, 2005;
106(4):
1346 - 1354.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Boulay, J. Rudloff, J. Ye, S. Zumstein-Mecker, T. O'Reilly, D. B. Evans, S. Chen, and H. A. Lane
Dual Inhibition of mTOR and Estrogen Receptor Signaling In vitro Induces Cell Death in Models of Breast Cancer
Clin. Cancer Res.,
July 15, 2005;
11(14):
5319 - 5328.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. S. Hammerman, C. J. Fox, M. J. Birnbaum, and C. B. Thompson
Pim and Akt oncogenes are independent regulators of hematopoietic cell growth and survival
Blood,
June 1, 2005;
105(11):
4477 - 4483.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. E. Winters, A. I. Mehta, E. F. Petricoin III, E. C. Kohn, and L. A. Liotta
Supra-additive Growth Inhibition by a Celecoxib Analogue and Carboxyamido-triazole Is Primarily Mediated through Apoptosis
Cancer Res.,
May 1, 2005;
65(9):
3853 - 3860.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Schachner, A. Oberhuber, Y. Zou, A. Tzankov, H. Ott, G. Laufer, and J. Bonatti
Rapamycin treatment is associated with an increased apoptosis rate in experimental vein grafts
Eur. J. Cardiothorac. Surg.,
February 1, 2005;
27(2):
302 - 306.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Jernberg-Wiklund and K. Nilsson
Toward a rational combinaTORial therapy for multiple myeloma
Blood,
December 15, 2004;
104(13):
3845 - 3846.
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Frost, F. Moatamed, B. Hoang, Y. Shi, J. Gera, H. Yan, P. Frost, J. Gibbons, and A. Lichtenstein
In vivo antitumor effects of the mTOR inhibitor CCI-779 against human multiple myeloma cells in a xenograft model
Blood,
December 15, 2004;
104(13):
4181 - 4187.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Raje, S. Kumar, T. Hideshima, K. Ishitsuka, D. Chauhan, C. Mitsiades, K. Podar, S. Le Gouill, P. Richardson, N. C. Munshi, et al.
Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma
Blood,
December 15, 2004;
104(13):
4188 - 4193.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
